6.Do K, Doroshow JH, Kummar S. Wee1 kinase as atarget for cancer therapy. Cell Cycle. 2013 Oct 1;12(19):3159-64. doi:10.4161/cc.26062. Epub 2013 Aug 26. PMID: 24013427; PMCID: PMC3865011. 7.Moiseeva TN, Qian C, Sugitani N, Osmanbeyoglu HU,Bakkenist CJ. WEE1 kinase inhibit...
7、Lezina L,Purmessur N, Antonov AV, et al. miR-16 and miR-26a target checkpoint kinasesWee1 and Chk1 in response to p53 activation by genotoxic stress. Cell death& disease. 2013 Dec;4(12):e953-. 8、Hamer PC, MirSE, Noske D...
[7] Ma M, Rodriguze A, Sugimoto K, et al. Activation of ATR-related protein kinase upon DNA damage recognition[J]. Curr Genet, 2020, 66(2): 327-333. [8] Mueller S, Haas-Kogan D A. WEE1 Kinase as a targe...
1、Structure-activity relationships of Wee1 inhibitors: A review(2020); 2、A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target(2020); 3、Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in tripleneg...
PD0166285不仅是一种高效的Wee1抑制剂(IC50值为24 nM)和Chk1(IC50值为72 nM)抑制剂,还是一种新型的G2检查点抑制剂,且能够诱导细胞凋亡。 产品性质 英文别名 (English Synonym) PD0166285 中文名称 (Chinese Name) / 靶点 (Target) Chk1 Myt1 Wee1 通路 (Pathway) Apoptosis CAS号 (CAS NO.) 18503...
Target Wee1/Myt1 Program Type Proprietary, small molecule Indication Solid tumors Stage Phase 1 clinical development Overview SGR-3515 is a Wee1/Myt1 inhibitor. Wee1 and Myt1 (membrane associated tyrosine/threonine 1) kinases regulate the cell cycle and DNA damage response through phosphorylation ...
Do K, Doroshow JH, Kummar S (2013) Wee1 kinase as a target for cancer therapy. Cell Cycle 12:3159–3164 CentralDo K, Doroshow JH, Kummar S (2013) Wee1 kinase as a target for cancer therapy. Cell Cycle 12(19):3159-3164. doi:10.4161/ cc.26062...
Target-Focused Phenotypic Screening Library L95001796 化合物 产品详情 选择批次: 纯度:99.23% 联系我们获取更多批次信息 资源下载 DataSheetSDSCOALCMSHNMRHPLC产品操作手册 产品介绍 生物活性 产品描述 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel...
DNA repair dysregulation from cancer driver to therapeutic target [J]. Nat Rev Cancer, 2012, 12(12): 801-817. [17] Vriend L E, De Witt Hamer P C, Van Noorden C J, et al. WEE1 inhibition and genomic instability in cancer [J]. Biochim Biophys Acta, 2013, 1836(2): 227-235. [...
Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of MRANK-106 in p...